Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVX: IVAX Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (74)	11/28/2005 12:42:54 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 78

EU Clears Israeli Drug Co Teva To Buy Ivax DOW JONES NEWSWIRES November 25, 2005 4:35 a.m. BRUSSELS -- The European Commission Friday cleared Israel's Teva Pharmaceutical Industries Ltd. (TEVA) to buy U.S.-based drug maker Ivax Corp. (IVX). After a month-long investigation, the regulator found the combined companies would still face strong competition in the generic drugs business. The Commission examined the companies overlapping drugs and active ingredients businesses, and concluded the increase in market share in these areas is "very limited." Teva is buying Ivax for about $7.4 billion. Teva specializes in the development, production and marketing of generic pharmaceuticals and active ingredients used to make a range of drugs. Ivax is active in the research, development and marketing of branded and generic drugs and veterinary products